Search

Our Company

News & Latest Announcements

Latest News

The EU-X-CT 6-Point Action Plan: A Blueprint for a New Generation of CROs
03 November 2025
The EU-X-CT 6-Point Action Plan: A Blueprint for a New Generation of CROs
The Future of CAR-T cell Therapies in Autoimmune Disease: From Concept to Clinical Reality
27 October 2025
The Future of CAR-T cell Therapies in Autoimmune Disease: From Concept to Clinical Reality
CTR, GDPR, and the Cross-Border Void: Navigating the Legal Maze of Pan-European Trials
27 October 2025
CTR, GDPR, and the Cross-Border Void: Navigating the Legal Maze of Pan-European Trials
Scaling CAR-T: Manufacturing, Allogeneic Solutions, and CRO Readiness 
21 October 2025
Scaling CAR-T: Manufacturing, Allogeneic Solutions, and CRO Readiness 
The Patient Who Can’t Wait: Why Personalized Support is Key in Cross-Border Trials
20 October 2025
The Patient Who Can’t Wait: Why Personalized Support is Key in Cross-Border Trials
Europe’s Clinical Trial Ecosystem: A Ticking Clock for Biotech Innovators?
15 October 2025
Europe’s Clinical Trial Ecosystem: A Ticking Clock for Biotech Innovators?
Mitigating Risks: How CROs Ensure Safe CAR-T cells Trials
14 October 2025
Mitigating Risks: How CROs Ensure Safe CAR-T cells Trials
Are You Ready to Lead the Patient-Centric Revolution?
08 October 2025
Are You Ready to Lead the Patient-Centric Revolution?
Inside the Trials: Early Evidence of CAR-T cell therapy in Progressive MS
07 October 2025
Inside the Trials: Early Evidence of CAR-T cell therapy in Progressive MS
Metrics That Matter: Measuring Patient Experience in Trials
01 October 2025
Metrics That Matter: Measuring Patient Experience in Trials
CAR-T cells vs. Anti-CD20 antibodies: Breaking Through the CNS Barrier in MS
29 September 2025
CAR-T cells vs. Anti-CD20 antibodies: Breaking Through the CNS Barrier in MS
Co-Created Protocols: Co-Writing the Protocol with Patients
24 September 2025
Co-Created Protocols: Co-Writing the Protocol with Patients
Why CAR-T Cell Therapy is Redefining Autoimmune Treatment
23 September 2025
Why CAR-T Cell Therapy is Redefining Autoimmune Treatment
Why DCT is Not Optional. It’s an Ethical and Business Imperative
17 September 2025
Why DCT is Not Optional. It’s an Ethical and Business Imperative
Why Biotechs Choose Specialized CROs
15 September 2025
Why Biotechs Choose Specialized CROs
Kid Gloves vs. Core Change: Is Your Trial Accommodating or Truly Re-engineered?
10 September 2025
Kid Gloves vs. Core Change: Is Your Trial Accommodating or Truly Re-engineered?
Patient-Centricity in Autoimmune CAR-T
08 September 2025
Patient-Centricity in Autoimmune CAR-T
Beyond Friendly: What True Patient Centric Trials Look Like
05 September 2025
Beyond Friendly: What True Patient Centric Trials Look Like
Your Regulatory Dream Team
01 September 2025
Your Regulatory Dream Team
Speed Without Compromise: CRO Flexibility
25 August 2025
Speed Without Compromise: CRO Flexibility
The High Stakes of Picking the Wrong CRO in Allogeneic Development
18 August 2025
The High Stakes of Picking the Wrong CRO in Allogeneic Development
Why Agility is the New Gold Standard in Allogeneic CAR-T Trials
18 August 2025
Why Agility is the New Gold Standard in Allogeneic CAR-T Trials
Advancing Phase I Clinical Research: Our Expertise in PK/PD Studies
16 May 2025
Advancing Phase I Clinical Research: Our Expertise in PK/PD Studies
Accelsiors at Swiss Biotech Days 2025: Bridging Innovation, Cultures, and Chocolate
12 May 2025
Accelsiors at Swiss Biotech Days 2025: Bridging Innovation, Cultures, and Chocolate

Accelsiors is a full-service global CRO.

We are on a mission to accelerate development of tomorrow’s life-changing therapies of emerging biotech companies.

Accelsiors is a full-service global CRO.
We are on a mission to accelerate development of tomorrow’s life-changing therapies of emerging biotech companies.

Locations
Privacy Policy
& Terms of Use
Accelsiors CRO

www.accelsiors.com
© Accelsiors 2025 – All rights reserved